Table 4Summary GRADE table for pharmacological management of the underlying sickling process: tinzaparin compared with placebo

Number of studiesTreatmentPlaceboMeasure of effectQualityImportance
Duration of the painful episode in adults
Qari et al. (2007)tinzaparinsalineMD = −1.78 days (CI −1.94, −1.62)LowImportant
Adverse events in adults
Qari et al. (2007)tinzaparinsalineTinzaparin treatment was associated with two minor bleeding events that were reported and treated by cessation of treatmentLowCritical
Length of stay (LOS) in adults
Qari et al. (2007)tinzaparinsalineMD = −4.98 days (CI −5.48, −4.48)LowCritical

Abbreviations: CI, confidence interval; MD, mean difference.

From: 2, Evidence review and recommendations

Cover of Sickle Cell Acute Painful Episode
Sickle Cell Acute Painful Episode: Management of an Acute Painful Sickle Cell Episode in Hospital.
NICE Clinical Guidelines, No. 143.
Centre for Clinical Practice at NICE (UK).
Copyright © 2012, National Institute for Health and Clinical Excellence.

All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.